Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Med Res Opin. 2008 Aug;24(8):2151-7. doi: 10.1185/03007990802237343. Epub 2008 Jun 17.

Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial--a prospective pilot study.

Author information

  • 1Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Abstract

OBJECTIVE:

Sudden cardiac (arrhythmic) death (SCD) is the single largest cause of death in dialysis patients. Prophylactic Implantable Cardioverter Defibrillator (ICD) therapy reduces SCD and reduces all-cause mortality in several groups of patients at high risk for arrhythmic death. Whether this also applies to dialysis patients is unknown.

RESEARCH DESIGN AND METHODS:

The Implantable Cardioverter Defibrillator in Dialysis patients (ICD2) trial is a prospective randomised controlled study. It has been designed to evaluate the efficacy and safety of prophylactic ICD therapy in reducing sudden cardiac death rates in dialysis patients aged 55-80 years. A total of 200 patients will be included. The primary endpoint of the study is sudden cardiac (arrhythmic) death. The mean follow-up time will be 4 years.

TRIAL REGISTRATION:

'The Netherlands Trial Register'--ISRCTN20479861

CONCLUSION:

The ICD2 trial--a pilot study--will be the first study to evaluate the possible benefit of ICD therapy for the primary prevention of sudden cardiac death in dialysis patients.

PMID:
18561878
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk